United Therapeutics Corporation Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- United Therapeutics Corporation stock issued during period, value, conversion of convertible securities for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
- United Therapeutics Corporation stock issued during period, value, conversion of convertible securities for the quarter ending 2016-09-30 was $1.40M, a 80.82% decline year-over-year.
- United Therapeutics Corporation stock issued during period, value, conversion of convertible securities for the quarter ending 2016-06-30 was $6.00M, a 97.45% decline year-over-year.
- United Therapeutics Corporation stock issued during period, value, conversion of convertible securities for the quarter ending 2016-03-31 was $100.00K, a 99.64% decline year-over-year.
- United Therapeutics Corporation stock issued during period, value, conversion of convertible securities for fiscal 2016 was $7.50M, a 97.67% decline from fiscal 2015.
- United Therapeutics Corporation stock issued during period, value, conversion of convertible securities for fiscal 2015 was $321.80M, a 69.99% increase from fiscal 2014.
- United Therapeutics Corporation stock issued during period, value, conversion of convertible securities for fiscal 2014 was $189.30M.
- United Therapeutics Corporation stock issued during period, value, conversion of convertible securities for fiscal 2011 was $27.29M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $7.50M 10-K · filed 2019-02-27 |
| 2016-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-25 | $58.70M derived: sum of 4 quarters · filed 2018-02-21 |
| 2016-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | $64.60M derived: sum of 4 quarters · filed 2018-02-21 |
| 2016-03-31 | $100.00K 10-Q · filed 2017-04-26 | $294.10M derived: sum of 4 quarters · filed 2018-02-21 |
| 2015-12-31 | $51.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $321.80M 10-K · filed 2018-02-21 |
| 2015-09-30 | $7.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27 | |
| 2015-06-30 | $235.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | |
| 2015-03-31 | $27.80M 10-Q · filed 2016-04-28 | |
| 2014-12-31 | $189.30M 10-K · filed 2017-02-22 | |
| 2011-12-31 | $27.29M 10-K · filed 2014-02-25 | |
| 2010-12-31 | -$1.00K 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |